Navigation Links
Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
Date:1/5/2012

GREENWOOD VILLAGE, Colo., Jan. 5, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it will hold a Web Cast on Thursday, January 26, 2012 at 4:15 EST. The purpose of the call will be to update our shareholders on the company's progress and a press release on January 16th will announce how the shareholders and the general public can join and listen to the call. 

The company will present a 30-minute overview of the company's progress and future plans and then open the call to a Q & A session.  The subjects covered will include:

  • Ampio's sexual dysfunction drug portfolio Zertane™, for the treatment of premature ejaculation (PE) and a combination drug that combines Zertane™ and a PDE5 inhibitor for simultaneous treatment of PE and erectile dysfunction (ED)
  • Ampio's anti-inflammatory drug Ampion™, and an update on the Australian clinical trial for the treatment of Osteoarthritis in the knee
  • Ampio's vascular permeability drug Optina™, and an update on the Canadian Phase II clinical trial for the treatment of patients with Diabetic Macular Edema (DME), which is a common complication of Diabetes Mellitus

"Our progress in 2011 and our clinical plans going forward are difficult to explain in periodic press releases." said Michael Macaluso, Ampio's Chairman. "This format will allow a more nuanced presentation of the direction that Ampio has taken, as well as the short term future plans for each of our products."

Homework for shareholders

For those shareholders who would like to prepare for this webcast by reviewing a few of Dr. Bar-Or's peer-reviewed articles reporting early research on these products, please click on the articles below:

Re: Zertane™ :

Re: Ampion

Re: Optina™

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.  

Forward-Looking Statements                                                                                                          
Ampio's statements made in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions.  These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events.  The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact
Investor Relations, 
Ampio Pharmaceuticals, Inc.
 720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
2. Ampio Responds to Recent Publications by Anonymous Short Sellers
3. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
4. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
5. Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
6. Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
7. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
8. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
9. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
10. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
11. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb 17, 2017 Research and Markets ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:2/17/2017)... ST. LOUIS , Feb. 17, 2017   ... hospitals, has announced a new partnership with Engage ... the United States . FormFast will serve ... part of Engage,s implementations with MEDITECH .  ... that provides essential functionality to complement and enhance the ...
(Date:2/17/2017)... 17, 2017 On Thursday, February ... edged lower at the closing bell, while the Dow ... 20,000 benchmark. Moreover, five out of nine sectors ended ... yesterday,s market sentiment, Stock-Callers.com assessed the following Medical Appliances ... (NYSE: SNN ), ABIOMED Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital is ... Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital within ... nation. While many providers are struggling to leverage limited resources and technology, Onslow Memorial ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason ... to families and business owners in and around the Hampton Roads metropolitan region, ... prevent all forms of domestic violence. , There are multiple categories of domestic ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati knows the ... research, development and clinical trials, the founder of Chigurupati Technologies has invented India’s ... FDA approved ingredients that when infused into alcohol, protect the consumer’s liver and ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children is the ... (pediatrics) is being created with the support of the Hearst Foundations. An initiative of ... will address what has been identified as a critical gap in preparing the next ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection of ... NWH has achieved Magnet® recognition for the second time, announced by ... American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet rigorous standards ...
Breaking Medicine News(10 mins):